Core Viewpoint - Changmao Biological (00954) reported a decline in revenue and an increase in losses for the first half of 2025, primarily due to external geopolitical factors and changes in product demand and pricing [1] Financial Performance - Revenue for the first half of 2025 was approximately 272 million yuan, representing a year-on-year decrease of 13.23% [1] - The loss attributable to shareholders was 25.79 million yuan, an increase of 37.28% compared to the previous year [1] - Earnings per share showed a loss of 0.049 yuan [1] Contributing Factors - The decline in performance was influenced by external factors such as geopolitical conflicts and uncertainties in tariff policies [1] - Demand for downstream products of phthalic anhydride was below expectations, and the release of new production capacity altered the supply-demand balance, indirectly affecting product prices and profitability [1] - The increase in interest expenses in the consolidated income statement was due to a reduction in the amount of capitalized interest on qualifying assets [1]
常茂生物公布中期业绩 股东应占亏损为2579万元 同比增长37.28%